Novartis’ Kisqali (ribociclib) has been approved by the US Food and Drug Administration (FDA) as part of a combination ...

Rybrevant (amivantamab-vmjw) combination has demonstrated a positive overall survival trend in adults with lung cancer, ...

Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...

GSK has shared positive headline results for its mRNA seasonal influenza vaccine and outlined that it will now progress the ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

The pharmaceutical industry is committed to the development, manufacture and provision of medicines globally, a process that inevitably impacts the climate through greenhouse gases (GHG). To mitigate ...

Sanofi and Regeneron’s Dupixent (dupilumab) has demonstrated significant improvements in itch and hives for patients with chronic spontaneous urticaria (CSU), according to late-stage results shared by ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...